The use of glucagon-like peptide-1 (GLP-1) receptor-based multi-agonists in the treatment of
type 2 diabetes and obesity holds great promise for improving glycaemic control and weight …

Apelin, a novel endogenous ligand of the G-protein-coupled receptor APJ, is encoded by the
APLN gene and can be hydrolyzed into multiple subtypes, with Apelin-13 being one of the …

Aim To evaluate the effects of single PPARα or PPARγ activation, and their synergism
(combined PPARα/γ activation) upon the gut-adipose tissue axis, focusing on the …

Oral biotherapeutics hold significant promise, but their lack of controllability and targeting
poses a major challenge, particularly for intestinal bacterial biotherapeutics. In response, we …

Negatively charged poly (l-Thr-co-l-Thr succinate)(PTTs) was developed as a new
thermogel. Aqueous PTT solutions underwent thermogelation over a concentration range of …

The ability of CDK1 to compensate for the absence of other cell cycle CDKs poses a great
challenge to treat cancers that overexpress these proteins. Despite several studies focusing …

Although glucose, as a secretagogue of intestinal hormone, can stimulate glucagon‐like
peptide 1 (GLP‐1) release, it has not been fully elucidated how glucose triggers GLP‐1 …

Mitochondrial damage caused by external stimuli, such as high glucose levels and
inflammation, results in excessive reactive oxygen species (ROS) production. Existing …

Objective N-acylethanolamines (NAEs) include endocannabinoid (EC) and EC-related
molecules that impact the anti-obesity and anti-diabetic efficacy of glucagon-like peptide-1 …

Incretin peptides are secreted from the intestine after nutrient ingestion and enhance
glucose-stimulated insulin secretion [1]. In healthy individuals glucagon-like peptide 1 (GLP …